Table 4.

Associations of glycemia with diabetic peripheral neuropathy stratified by CKD status

	CKD	Controls	P value for interaction
	Adjusted OR* (95% CI)	Adjusted OR* (95% CI)
Time in range (70–180 mg/dL) (per 10% lower)†	1.27 (1.01 to 1.61)	0.97 (0.61 to 1.53)	0.69
Time above range (>180 mg/dL) (per 10% higher)†	1.26 (1.01 to 1.58)	0.92 (0.58 to 1.47)	0.63
Per cent coefficient of variations (per 6% higher (1 SD))	1.04 (0.63 to 1.71)	3.10 (0.87 to 11.01)	0.37
GMI (per 1% higher)	1.93 (1.05 to 3.55)	0.68 (0.16 to 2.84)	0.58
HbA1c (per 1% or 11 mmol/mol higher)	1.33 (0.94 to 1.88)	0.48 (0.14 to 1.65)	0.83
Duration of diabetes (per 10 years longer)	1.16 (0.73 to 1.87)	0.91 (0.23 to 3.65)	0.58

Sixty-two of 105 participants with a total MNSI questionnaire score ≥2 were defined as having distal peripheral neuropathy in this analysis.

*adjusted for age, gender, and race

†10%=144 minutes/day

CKD, chronic kidney disease; GMI, glucose management indicator; HbA1c, hemoglobin A1c; MNSI, Michigan Neuropathy Screening Instrument.